DiaMedica Therapeutics - DMAC Stock Forecast, Price & News

3 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DiaMedica Therapeutics in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DMAC shares.
View DMAC analyst ratings or view top-rated stocks.

3 brokers have issued 12-month price targets for DiaMedica Therapeutics' stock. Their DMAC share price forecasts range from $8.00 to $12.00. On average, they anticipate the company's stock price to reach $10.00 in the next twelve months. This suggests a possible upside of 594.4% from the stock's current price.
View analysts price targets for DMAC or view top-rated stocks among Wall Street analysts.

DiaMedica Therapeutics' stock was trading at $3.73 at the beginning of 2022. Since then, DMAC stock has decreased by 61.4% and is now trading at $1.44.
View the best growth stocks for 2022 here.

DiaMedica Therapeutics saw a drop in short interest during the month of November. As of November 15th, there was short interest totaling 34,500 shares, a drop of 35.0% from the October 31st total of 53,100 shares. Based on an average trading volume of 56,600 shares, the short-interest ratio is presently 0.6 days. Currently, 0.2% of the company's stock are sold short.
View DiaMedica Therapeutics' Short Interest.

The company is scheduled to release its next quarterly earnings announcement on Monday, March 13th 2023.
View our DMAC earnings forecast.

DiaMedica Therapeutics Inc. (NASDAQ:DMAC) issued its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.18) earnings per share for the quarter, topping the consensus estimate of ($0.23) by $0.05. During the same period in the previous year, the business earned ($0.19) EPS.

Based on aggregate information from My MarketBeat watchlists, some companies that other DiaMedica Therapeutics investors own include VBI Vaccines (VBIV), Inovio Pharmaceuticals (INO), Dynavax Technologies (DVAX), Pfizer (PFE), Vaxart (VXRT), Aldeyra Therapeutics (ALDX), Capricor Therapeutics (CAPR), Oncolytics Biotech (ONCY), Sesen Bio (SESN) and Sorrento Therapeutics (SRNE).

(DMAC) raised $18 million in an initial public offering on Friday, December 7th 2018. The company issued 4,000,000 shares at $4.00-$5.00 per share. Craig-Hallum Capital Group served as the underwriter for the IPO.

DiaMedica Therapeutics trades on the NASDAQ under the ticker symbol "DMAC."

DiaMedica Therapeutics' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Dimensional Fund Advisors LP (0.16%) and Citadel Advisors LLC (0.13%). Insiders that own company stock include Dietrich John Pauls, Harry W Alcorn Jr, Koch Thomas Von, Randall Michael Giuffre, Richard D Pilnik and Scott Kellen.
View institutional ownership trends.

Shares of DMAC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of DMAC stock can currently be purchased for approximately $1.44.

DiaMedica Therapeutics (NASDAQ:DMAC) has a market capitalization of $38.07 million. The company earns $-13,590,000.00 in net income (profit) each year or ($0.48) on an earnings per share basis.

DiaMedica Therapeutics' mailing address is 2 CARLSON PARKWAY SUITE 260, MINNEAPOLIS MN, 55447. The official website for the company is www.diamedica.com. The company can be reached via phone at (763) 312-6755 or via email at skellen@diamedica.com.